Showing posts with label biotech. Show all posts
Showing posts with label biotech. Show all posts

Thursday, May 2, 2013

Latest Edition of DIA's Content Currents is available (April 26, 2013)

DIA

DIA's Content Currents provides you with new and important global regulatory developments and their impact on pharmaceutical, biotechnology, and medical product development.


EDITION PUBLISHED: APRIL 26, 2013


SECTION 1: FDA GUIDANCES
April 23, FDA announced the availability of a draft guidance document for industry entitled, “Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors.” This draft guidance is intended to aid prescription drug and biologic manufacturers in minimizing medication errors by focusing on safety aspects of the container label and carton labeling design. The 60 day comment period will close June 22, 2013. [Draft Guidance] (FDA.gov)

April 23, FDA announced the availability of a draft guidance document entitled, “Use of International Standard ISO-10993, ‘Biological Evaluation of Medical Devices Part 1: Evaluation and Testing.’” This draft guidance is intended to aid sponsors in determining the potential toxicity of medical devices contacting the skin, clarify the Office of Device Evaluation General Program Memorandum #G95-1, and replace the memorandum when made final. [Draft Guidance] [FR Notice]

April 25, FDA announced the availability of a final guidance document entitled, “Assay Migration Studies for In Vitro Diagnostic Devices.” This guidance document is intended to provide a least burdensome approach to earn FDA approval of Class III or certain licensed in vitro diagnostic devices in cases when an already approved assay is transitioning to a new system. [Guidance]

April 25, FDA also announced the availability of a final guidance document for industry entitled, “Regulatory Classification of Pharmaceutical Co-Crystals.” This guidance document is intended to aid sponsors of new drug applications (NDAs) and abbreviated new drug applications (ANDAs) by informing them of the type of data that should be submitted to support the application. [Guidance] Note: the link appears to be temporarily unavailable as of 4/25/13. (FDA.gov)


For complete update, please visit http://www.diahome.org/~/link.aspx?_id=CA3173B02837442185CDC0BFA47C58F0&_z=z


Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.

Monday, April 22, 2013

How is translational medicine defined globally? What are the potential benefits for industry and academia?

Understanding Translational Medicine: Benefits and Innovative Approaches
June 23 from 1:00PM – 4:30PM in Boston


This tutorial will help the professionals working at various positions in the pharma, biotech, medical device industries and academia to better understand translational medicine. Translational Medicine has great potential to enhance health care starting from prevention, diagnosis, and drug/device developments for clinical disorders. However, there are few clinician/scientists critically trained in translational research and more programs to foster their development are required. This tutorial will provide an overview of the translational medicine field including definitions and concepts, potential benefits as well as global initiatives and programs.


Instructor(s):
Aamir Shahzad, MD
President
European Society For Translational Medicine (EUSTM), Austria


What’s more…Receive $100 off of your DIA 2013 Annual Meeting registration by registering for two half day tutorials or one full day tutorial. Please note purchases must be made at the same time in order to receive the discount.


Visit www.diahome.org/DIA2013 for more details on the DIA 2013 Annual Meeting being held June 23-27 in Boston, MA.


Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.

Thursday, April 18, 2013

DIA's Content Currents | APRIL 12, 2013

DIA


DIA's Content Currents provides you with new and important global regulatory developments and their impact on pharmaceutical, biotechnology, and medical product development.




EDITION PUBLISHED: APRIL 12, 2013

SECTION 1: FDA GUIDANCES
SECTION 2: FDA NOTES & RELATED NEWS
SECTION 3: AGENCY AND ADVISORY COMMITTEE MEETINGS

SECTION 4: OTHER REGULATORY AUTHORITIES & ORGANIZATIONS
SECTION 5: COMPLIANCE & LEGAL NEWS


SECTION 1: FDA GUIDANCES

April 12, FDA announced the availability of a draft guidance document entitled, “M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.” This draft guidance is intended to provide recommendations and a framework that can be applied for the identification, categorization, qualification, and control of mutagenic impurities. [Draft Guidance] (FDA.gov) This document reached step 2 of the ICH process in February 2013, meaning that it was sent simultaneously to each of the ICH regions for internal and external consultation according to their regional procedures.

April 11, FDA announced the availability of a final guidance document entitled, “Medical Device Classification Product Codes.” This guidance is intended to describe how FDA uses product codes to regulate and track medical devices. [
FR Notice]

April 10, FDA announced the availability of a final guidance document entitled, “Self-Selection Studies for Nonprescription Drug Products.” This guidance provides recommendations to industry on the study design, methodology and analyses of self-selection studies. Self-selection studies are used by regulators to determine whether a consumer can reasonably be expected to select an OTC product for an appropriate purpose and follow the labeling such that it is used appropriately. [
Guidance] (FDA.gov)

April 9, FDA announced the availability of a draft guidance document entitled, “Molecular Diagnostic Instruments with Combined Functions.” This draft guidance advises industry and agency staff members on the type of information that should be included in a submission for molecular diagnostic instruments that have both device and non-device functions. [
FR Notice]

Visit DIAHome.org for complete issue


Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.

Friday, April 12, 2013

Pharma professionals, looking for CE credit from PMI?

The DIA 2013 49th Annual Meeting is the premier event for professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related products.

 
Sign up today to have the latest news in drug development worldwide delivered to your inbox ~ DIA's Global Smartbrief.

Wednesday, February 27, 2013

What Lies Ahead for 2013?

DIA's first annual What Lies Ahead? report, provides expert insight into the year ahead for pharmaceuticals, biotechnology, and the product development of medical devices.


With thought leaders from industry and academia asked to choose the trends they foresee shaping the world of medical product development in 2013 most agreed that the number one trend for this year will be “new models of innovation.” Based on the report, it is highly anticipated that industry will focus on collaboration and partnerships which are becoming the new norm for therapeutic research and development as companies look to capitalize on innovations outside their own walls. The report points to shrinking industry R&D budgets as being a motivator for such partnerships. The desire to reduce the time to market for urgently needed medicines and to avoid needlessly exposing patients to previously failed approaches were highlighted as strong motivators as well.

Susan Cantrell, Director, North America at DIA said, “We are excited to provide insights into where the industry is heading each year and what may continue to grow in importance over the next few years. These projections of the future landscape can be valuable to companies as they strategize to successfully meet the ever-changing needs of the marketplace.”

The study shows expectations of 2013 are that of the continued strengthening of consumer/patient empowerment (2nd most expected trend), a focus on unmet medical needs as the driver for innovations, and growing regulatory cooperation and convergence across multiple regions.

“While this study is specific to North America, and the United States in particular, as the global forum for therapeutic innovation and regulatory science we anticipate it being useful on a worldwide scale,” said Cantrell.

Therapeutic Innovation & Regulatory Science in 2013

1. New Models of Innovation.

2. The Continued Rise of Patient/Consumer Empowerment: the Importance of Patient/Consumer Engagement.

3. Learning How to Utilize Big Data.

4. Achieving Market Access is the New Goal, and Value Is a Key Driver.

5. Regulatory Cooperation and Convergence.

6. Personalized Medicine/Tailored Therapies and Companion Diagnostics.

7. An Explosion of Mobile Health Applications.

8. Continued Importance of Global Markets.*

9. Clinical Trial Data Transparency.*

10. Growing Ability to Make Meaningful Benefit–Risk Assessments.*

11. Laser Focus on Unmet Medical Needs.*

*Trends 8-11 each received the same number of votes for inclusion in the “Top 10” trends.

12. The Era of Data Standardization Is Here.

To obtain a copy of the study or to interview a respondent, please contact Eric Rosen at Eric.Rosen@diahome.org or at +1.215.290-9153.
- See more at: http://www.diahome.org/en/News-and-Publications/Newsroom/What-Lies-Ahead-in-2013.aspx?_id=DDD6EB0B232743E691EF5C3AE65D9F42&_z=z#sthash.MK9eJL9M.dpuf

Wednesday, October 24, 2012

Europe Establishes First Facility for Cell-Based Therapeutics




On Oct. 22, 2012, a consortium in France announced the establishment of Europe’s first ever industrial manufacturing facility dedicated to the large-scale production of novel, advanced cell-based therapy medicinal products. The plant, located in Les Ulis, near Paris, at the site of the French biopharmaceutical company LFB Biotechnologies, has the capacity to produce 3000 to 5000 therapeutic batches per year. The facility will be used for innovative R&D projects on autologous and allogeneic cell therapies that are progressing from early clinical research stage up to industrial production.

http://www.pharmtech.com/pharmtech/News/Europe-Establishes-First-Facility-for-Cell-Based-T/ArticleStandard/Article/detail/793994?contextCategoryId=35097&ref=25

Tuesday, October 23, 2012

Pharma & Biotech Companies Donate Hundreds of Millions of Dollars to Copayment Foundations. Here’s Why.

from BIOtechNow


 
In addition to using their own Patient Assistance Programs, many pharma and biotech companies are supporting independent 501(c)3 non-profit copayment foundations to increase treatment compliance, access to care for insured Americans (including Medicare patients), and to promote proper disease management.
Mary SundeenMary P. Sundeen, President, HealthWell Foundation
Copayment foundations have helped hundreds of thousands of insured Americans afford their coverage and their treatments. The HealthWell Foundation, one of the nation’s largest non-profits, recently issued a white paper on copayment assistance as a primer for pharmaceutical and biotechnology personnel. Our goal is to assist with reducing a manufacturer’s exposure to legal pitfalls and to maximize their charitable donation.

for complete article:

Pharma & Biotech Companies Donate Hundreds of Millions of Dollars to Copayment Foundations. Here’s Why.

Tuesday, October 16, 2012

BIO Travels to Brazil to Support the Ecosystem of Innovation

 
Government policies that support innovation are critical as the biotechnology industry seeks to develop innovative healthcare, agricultural, industrial and environmental biotechnology products and provide them to people all around the world. Innovation requires not only scientific research and commercial expertise, but also supportive and dynamic governments that help facilitate long-term growth of the industry.

Brazil has recognized the value of innovation in maintaining a robust, diversified economy that can compete in the 21st century, and declared biotechnology a national priority. Boosting biotech within Brazil has the potential to create high paying jobs and develop a healthier, more productive workforce.

This week BIO will be in Brazil for a roundtable meeting with representatives from Brazil’s National Committee on Biotechnology (or Comité Nacional de Biotecnologia (CNB)), representing close to a dozen relevant government agencies and ministries including the Ministry of Trade’s Innovation Secretariat, Ministry of Agriculture, Ministry of Health and Ministry of Science, Technology & Innovation.

for complete article: BIO Travels to Brazil to Support the Ecosystem of Innovation

Monday, October 8, 2012

(Reuters) - Life-sciences and health investing, long shunned by venture-capital investors, is making a comeback.

Several venture firms globally have each raised or are raising funds this year in the $200 million to $400 million range dedicated to life sciences, biotech and medicine, while others have raised large, diversified funds with big chunks dedicated to those fields.

Venture capitalists are taking that money and pushing it into several life-sciences and health-related fields. Last year, venture backers invested $4.82 billion in biotechnology, up 24 percent from 2010. Medical-devices venture investment rose 17 percent last year, and healthcare services rose 41 percent.

http://www.reuters.com/article/2012/09/24/us-venture-capital-life-sciences-idUSBRE88N0EK20120924

Friday, September 21, 2012

Central Ohio Has Fastest-Growing Bioscience Industry.

The Columbus (OH) Business First (9/21, Ghose) reports, "Central Ohio is keeping up the fastest pace of growth in its bioscience industry of six regions in the state." According to a report released Sept. 19 by BioOhio trade group, Ohio has "1,281 companies and organizations employing 60,600 workers in fields encompassing medical and agricultural products and research, such as pharmaceutical companies and medical device manufacturers. Employment in the biological sciences increased by 16.5 percent in the state from 2000 to 2011 while overall state employment declined." The report says the sector "generated $4.6 billion in payroll in 2011 and the average wage is about $75,500, compared with the statewide average for all industries of $42,500."

Tuesday, September 4, 2012

DIA wants you to continue to benefit from opportunities to learn and grow professionally, year-round.


 
 
News & PublicationsMeetings & TrainingsSpeaking & PublishingNetworking &
CommunitiesExhibiting AdvertisingCareer Center
DIA’s Annual Meeting Comes Once a Year.
Were You There?
If you missed this year’s DIA Annual Meeting, you can now purchase content that was delivered at this year’s program! DIA wants you to continue to benefit from opportunities to learn and grow professionally, year-round.
     • View available presentations for 280 + educational offerings
       captured in digital audio with synchronized slides
     • Download available offerings in MP3 format to your mobile
       device for portable listening
     • Check out the DIA 2012 Annual Meeting final program and see
       all the special topics that were covered
The DIA 2012 48th Annual Meeting includes a comprehensive coverage of today's hottest topics, such as PDUFA V, biosimilars, tailored therapies, personalized medicine, social media, region-specific content, and much more!
Entire Meeting Package: $799.99
Individual Session Price: $59.99
Track Price: $199 - $299
Read issues of the DIA 2012 48th Annual Meeting "Show Daily"
DIA 2013 49th Annual Meeting Call for Abstracts Now Open!
DIA 2013 49th Annual Meeting
“Advancing Therapeutic Innovation and Regulatory Science”
June 23-27, 2013
Boston, MA
Submission Deadline: COB, September 12
See What You Missed at DIA 2012 48th Annual Meeting in Philadelphia…
Hear FDA's Margaret Hamburg discuss how three of the most influential regulatory agencies--FDA, EMA, and Health Canada--can collaborate to harmonize technical requirements under the ICH; establish confidentiality arrangements; collaborate on inspection pilots; exchange working level scientific and regulatory policies, procedures, and reports; and implement technical level "clusters" of agency reviewers. Read a complete session follow-up.
Questions?
For questions related to the content of the Annual Meeting program, email the Annual Meeting Team.
Technical Difficulties?
If you experience technical difficulties while purchasing, please contact multiviewmediasupport@multiview.com or call 289-695-5400.
Note: Continuing education credits are NOT available for archived content accessed through the Live Learning Center. Content available for 18 months and will expire on
December 28, 2013.
 FacebookLinkedInTwitterYouTube
 

Monday, August 13, 2012

CALL FOR ABSTRACTS: #DIA2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science - deadline 9/12


http://www.diahome.org/en/Get-Involved/Submit-Abstracts/Submit-a-New-Abstract/Select-Meeting/Meeting-Details.aspx?productID=30075&productcode=13001

Meeting Date:
6/23/2013 8:30:00 AM - 6/27/2013 12:45:00 PM
Location:
Boston Convention and Exhibition Center 415 Summer Street, Boston, MA 02210 USA
Overview:

Call for Abstracts for DIA 2013 49th Annual Meeting opens as of August 6, 2012 with a deadline of September 12, 2012
· Read the Call for Abstracts to review specific guidelines for submitting an abstract for consideration
· Read Best Practices for submitting abstracts
DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science is the largest multidisciplinary event that brings together a global network of professionals to foster innovation that will lead to the development of safe and effective health care products.
Through increased access to training and expanded professional networking opportunities, DIA 2013 will:
· Provide a global unbiased platform to raise the level of discussion to facilitate innovation that will change the future of health care
· Provide comprehensive coverage of the full development and life cycle management process for all health care products Enhance your working relationship with colleagues, both locally and internationally
· Offer a holistic and integrated approach to the development and life cycle management of regulated health care products
Ultimately, collaboration is about mutual respect, working together, and being open to new ideas and learning from each other. To that end, DIA 2013 provides the best opportunity to meet with people from around the world, share your views and knowledge, network, and build new relationships.
Learning Objective:
At the conclusion of this meeting, participants should be able to:
  • Describe the current regulatory and public policy environment pertaining to pharmaceuticals with an emphasis on the Food and Drug Administration;
  • Discuss the international regulations and economic factors that impact the global biopharmaceutical industry;
  • Recognize the challenges facing the FDA and the pharmaceutical industry in areas such as research study design and statistical methodology;
  • Recognize state-of-the-art clinical and statistical systems and implementations;
  • Recognize the written and communication skills needed to promote your career and your companys objectives;
  • Enhance your working relationship with colleagues, both locally and internationally;
  • Describe legal, advertising, and marketing issues related to providing product information;
  • Discuss statistics, economics, and quality of life science;
  • Enhance your knowledge of risk assessment and management in the areas such as computer systems validation and drug safety and pharmacovigilance;
  • Discuss issues in safety reporting, data analysis, epidemiology, and regulations regarding adverse events.
Target Audience:
This program is designed for the full continuum of disciplines in the pharmaceutical and related industries to improve your understanding and skills as related to issues and solutions for a variety of pharmaceutical development interest areas.